Wednesday, July 8, 2026

Patent intelligence · US

US 11447500

Thienopyridine derivatives and pharmaceutical composition comprising same

granted A61PA61P35/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 27
Patent details — US 11447500

Quick answer

US 11447500 (Thienopyridine derivatives and pharmaceutical composition comprising same) is held by Wellmarker Bio Co., LTD.. Status: granted. Granted Sep 20, 2022. Expires Sep 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
15
CPC classes
A61P, A61P35/00

More from Wellmarker Bio Co., LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12077601

    Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods

    BANYAN BIOMARKERS, INC. · Expires Aug 29, 2044

    granted
  2. US 11885817

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Expires Jan 25, 2044

    granted
  3. US 11692030

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Expires Jun 29, 2043

    granted
  4. US 11598782

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Expires Mar 2, 2043

    granted
  5. US 11186873

    Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)

    Wellmarker Bio Co., LTD. · Expires Nov 25, 2041

    granted
  6. US 11078298

    Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods

    BANYAN BIOMARKERS, INC. · Expires Jul 29, 2041

    granted
  7. US 11008622

    Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof

    Wellmarker Bio Co., LTD. · Expires May 13, 2041

    granted

Frequently asked questions

What is US patent 11447500?

US 11447500 (Thienopyridine derivatives and pharmaceutical composition comprising same) is held by Wellmarker Bio Co., LTD.. Status: granted. Granted Sep 20, 2022. Expires Sep 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11447500?

Wellmarker Bio Co., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.

When does US 11447500 expire?

Our index shows an expiration date of Sep 15, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.